NCT04690855View on ClinicalTrials.gov

A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

February 18, 2022

Study Completion Date

December 20, 2022

Conditions
Breast CancerTriple Negative Breast Cancer
Interventions
DRUG

Talazoparib

Talazoparib 1 mg Orally Day 1 to Day 28

DRUG

Atezolizumab

Atezolizumab 840 mg IV over 60 minutes Day 15 of Cycle 1 then Day 1 and Day 15 of subsequent Cycles

RADIATION

Radiation

Radiation 8 Gy will be given in 3 fractions QOD beginning Day 12, 13 or 14 of Cycle 1 but 24-72 hours prior to 1st dose of Atezolizumab

Trial Locations (2)

30322

Winship Cancer Institute of Emory University, Atlanta

35294

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (2)

Genentech, Inc.
Pfizer
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Pfizer

INDUSTRY

collaborator

Emory University

OTHER

lead

Mylin A. Torres, MD

OTHER

NCT04690855 - A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter